Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2013

Pritchard Antonia L, Hayward Nicholas K

Abstract excerpt

Receptor tyrosine kinases are a diverse family of transmembrane proteins that can activate multiple pathways upon ligation of the receptor, one of which is the series of mitogen-activated protein kinase (MAPK) signaling cascades. The MAPK pathways play critical roles in a wide variety of cancer types, from hematologic malignancies to solid tumors. Aberrations include altered expression levels and activation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Mitogen-Activated Protein Kinases

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 23406774
DOI: 10.1158/1078-0432.CCR-12-0383

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.PMID 23406774Read ↗

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Semantic proximity Read ↗

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Semantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.